Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progression

Brain, Behavior, and Immunity

Volumn 24, Issue 6, 2010, Pages 952-958

  Avraham, Roi ^a   Benish, Marganit ^a   Inbar, Shelly ^a   Bartal, Inbal ^a   Rosenne, Ella ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Endocrinology; Immunotherapy; NK cells; Rats; Surgery

Indexed keywords

CATECHOLAMINE; INDOMETACIN; INTERLEUKIN 12; NADOLOL; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HORMONE ANTAGONIST; IMMUNOLOGICAL ADJUVANT; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL STRAIN; CELL STRAIN CRNK 16; CELL STRAIN MADB 106; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOCRINE BLOCKER THERAPY; FISCHER 344 RAT; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; ISOTOPE LABELING; LAPAROTOMY; LEUKEMIA; LUNG METASTASIS; MARGINATING PULMONARY NATURAL KILLER CELL; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LUNG TUMOR; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SURVIVAL; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CATECHOLAMINES; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; FLOW CYTOMETRY; HORMONE ANTAGONISTS; IMMUNE TOLERANCE; INDOMETHACIN; INTERLEUKIN-12; KILLER CELLS, NATURAL; LAPAROTOMY; LUNG NEOPLASMS; NADOLOL; NEOPLASMS, EXPERIMENTAL; POLY I-C; POSTOPERATIVE COMPLICATIONS; PROSTAGLANDIN ANTAGONISTS; RATS; RATS, INBRED F344; SURVIVAL;

EID: 77954219293     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.03.010     Document Type: Article

References (54)

1. Antoni M.H., Lutgendorf S.K., Cole S.W., Dhabhar F.S., Sephton S.E., McDonald P.G., Stefanek M., Sood A.K. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer 2006, 6(3):240-248.
2. Avraham R., Inbar S., Rosenne E., Ben-Eliyahu S. Autologous control of a highly malignant syngeneic CRNK-16 leukemia in the rat: a role for NK cells. Cancer Immunol. Immunother. 2006, 55(11):1348-1357.
3. Avraham, R., Schwartz, Y., Rosenne, E., Melamed, R., Ben-Eliyahu, S., 2004. IL-12-based immunotherapy reduces post-surgery immunosuppression and metastasis, and increases survival from experimental leukemia. Psychoneuroimmunology Research Society, Titisee, Germany, Elsevier.
4. Barlozzari T., Leonhardt J., Wiltrout R.H., Herberman R.B., Reynolds C.W. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J. Immunol. 1985, 134(4):2783-2789.
5. Barlozzari T., Reynolds C.W., Herberman R.B. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J. Immunol. 1983, 131(2):1024-1027.
6. Bar-Yosef S., Melamed R., Page G.G., Shakhar G., Shakhar K., Ben-Eliyahu S. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001, 94(6):1066-1073.
7. Ben-Eliyahu S., Page G.G., Schleifer S.J. Stress, NK cells, and cancer: still a promissory note. Brain Behav. Immun. 2007, 21(7):881-887.
8. Ben-Eliyahu S., Page G.G., Yirmiya R., Taylor A.N. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat. Med. 1996, 2(4):457-460.
9. Ben-Eliyahu S., Page G.G. In vivo assessment of natural killer cell activity in rats. Prog. Neuroendocrineimmunol. 1992, 5:199-214.
10. Benish M., Bartal I., Goldfarb Y., Levi B., Avraham R., Raz A., Ben-Eliyahu S. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 2008, 15(7):2042-2052.
11. Billiau A., Heremans H., Vermeire K., Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann. N. Y. Acad. Sci. 1998, 856:22-32.
12. Chehimi J., Valiante N.M., D'Andrea A., Rengaraju M., Rosado Z., Kobayashi M., Perussia B., Wolf S.F., Starr S.E., Trinchieri G. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol. 1993, 23(8):1826-1830.
13. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995, 270(5238):908.
14. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13(2):155-168.
15. Da Costa M.L., Redmond H.P., Finnegan N., Flynn M., Bouchier-Hayes D. Laparotomy and laparoscopy differentially accelerate experimental flank tumour growth. Br. J. Surg. 1998, 85(10):1439-1442.
16. Da Costa M.L., Redmond P., Bouchier-Hayes D.J. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery 1998, 124(3):516-525.
17. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., Anichini A. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 2007, 13(16):4677-4685.
18. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3(11):991-998.
19. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000, 52(4):595-638.
20. Eschwege P., Dumas F., Blanchet P., Le Maire V., Benoit G., Jardin A., Lacour B., Loric S. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995, 346(8989):1528-1530.
21. Faist E., Schinkel C., Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J. Surg. 1996, 20(4):454-459.
22. Folkman, J., 1995. Tumor angiogenesis. In: Medelsohn, P.M.H.J., Israel, M.A., Liotta, L.A. (Eds.), The Molecular Basis of Cancer. WB Saunders, Philadelphia.
23. Harbour-McMenamin D., Smith E.M., Blalock J.E. Bacterial lipopolysaccharide induction of leukocyte-derived corticotropin and endorphins. Infect. Immun. 1985, 48(3):813-817.
24. Hasko G., Elenkov I.J., Kvetan V., Vizi E.S. Differential effect of selective block of alpha 2-adrenoreceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J. Endocrinol. 1995, 144(3):457-462.
25. Hoodin F., Weber S. A systematic review of psychosocial factors affecting survival after bone marrow transplantation. Psychosomatics 2003, 44(3):181-195.
26. Kim R., Emi M., Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol. Ther. 2005, 4(9):924-933.
27. Lala P.K., Parhar R.S., Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol. 1986, 99(1):108-118.
28. Lee J.W., Shahzad M.M., Lin Y.G., Armaiz-Pena G., Mangala L.S., Han H.D., Kim H.S., Nam E.J., Jennings N.B., Halder J., Nick A.M., Stone R.L., Lu C., Lutgendorf S.K., Cole S.W., Lokshin A.E., Sood A.K. Surgical stress promotes tumor growth in ovarian carcinoma. Clin. Cancer Res. 2009, 15(8):2695-2702.
29. Malygin A.M., Meri S., Timonen T. Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2. Scand. J. Immunol. 1993, 37(1):71-76.
30. Melamed R., Rosenne E., Shakhar K., Schwartz Y., Abudarham N., Ben-Eliyahu S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 2005, 19(2):114-126.
31. Mitsuhashi M., Liu J., Cao S., Shi X., Ma X. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J. Leukoc. Biol. 2004, 76(2):322-332.
32. Pruett S.B., Fan R., Zheng Q. Acute ethanol administration profoundly alters poly I:C-induced cytokine expression in mice by a mechanism that is not dependent on corticosterone. Life Sci. 2003, 72(16):1825-1839.
33. Raskovalova T., Huang X., Sitkovsky M., Zacharia L.C., Jackson E.K., Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J. Immunol. 2005, 175(7):4383-4391.
34. Reynolds C.W., Bere E.W., Ward J.M. Natural killer activity in the rat. III. Characterization of transplantable large granular lymphocyte (LGL) leukemias in the F344 rat. J. Immunol. 1984, 132(1):534-540.
35. Rosenne E., Shakhar G., Melamed R., Schwartz Y., Erdreich-Epstein A., Ben-Eliyahu S. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav. Immun. 2007, 21(4):395-408.
36. Schwartz Y., Avraham R., Benish M., Rosenne E., Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res. Treat. 2007, 107(2):211-223.
37. Shakhar G., Abudarham N., Melamed R., Schwartz Y., Rosenne E., Ben-Eliyahu S. Amelioration of operation-induced suppression of marginating pulmonary NK activity using poly IC: a potential approach to reduce postoperative metastasis. Ann. Surg. Oncol. 2007, 14(2):841-852.
38. Shakhar G., Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 1998, 160(7):3251-3258.
39. Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann. Surg. Oncol. 2003, 10(8):972-992.
40. Shakhar G., Blumenfeld B. Glucocorticoid involvement in suppression of NK activity following surgery in rats. J. Neuroimmunol. 2003, 138(1-2):83-91.
41. Smith E.M., Blalock J.E. A molecular basis for interactions between the immune and neuroendocrine systems. Int. J. Neurosci. 1988, 38(3-4):455-464.
42. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001, 2(4):293-299.
43. Sood A.K., Bhatty R., Kamat A.A., Landen C.N., Han L., Thaker P.H., Li Y., Gershenson D.M., Lutgendorf S., Cole S.W. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 2006, 12(2):369-375.
44. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., Jennings N.B., Armaiz-Pena G., Bankson J.A., Ravoori M., Merritt W.M., Lin Y.G., Mangala L.S., Kim T.J., Coleman R.L., Landen C.N., Li Y., Felix E., Sanguino A.M., Newman R.A., Lloyd M., Gershenson D.M., Kundra V., Lopez-Berestein G., Lutgendorf S.K., Cole S.W., Sood A.K. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006, 12(8):939-944.
45. Trinchieri G. Immunobiology of interleukin-12. Immunol. Res. 1998, 17(1-2):269-278.
46. Tschuschke V., Hertenstein B., Arnold R., Bunjes D., Denzinger R., Kaechele H. Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study. J. Psychosom. Res. 2001, 50(5):277-285.
47. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 1995, 181(2):775-779.
48. Walker W., Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004, 111(3):298-305.
49. Walzer T., Dalod M., Vivier E., Zitvogel L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. 2005, 5(Suppl. 1):S49-S59.
50. Whalen M.M., Bankhurst A.D. Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem. J. 1990, 272(2):327-331.
51. Woiciechowsky C., Asadullah K., Nestler D., Eberhardt B., Platzer C., Schoning B., Glockner F., Lanksch W.R., Volk H.D., Docke W.D. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat. Med. 1998, 4(7):808-813.
52. Woiciechowsky C., Schoning B., Lanksch W.R., Volk H.D., Docke W.D. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J. Mol. Med. 1999, 77(11):769-780.
53. Yamaguchi K., Takagi Y., Aoki S., Futamura M., Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 2000, 232(1):58-65.
54. Zeddou M., Greimers R., de Valensart N., Nayjib B., Tasken K., Boniver J., Moutschen M., Rahmouni S. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochem. Pharmacol. 2005, 70(5):714-724.